307 related articles for article (PubMed ID: 21769849)
21. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis.
Liakouli V; Ciaffi J; Ursini F; Ruscitti P; Meliconi R; Ciccia F; Cipriani P; Giacomelli R
Expert Rev Clin Immunol; 2020 Sep; 16(9):931-942. PubMed ID: 32893688
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
Koon HB; Krown SE; Lee JY; Honda K; Rapisuwon S; Wang Z; Aboulafia D; Reid EG; Rudek MA; Dezube BJ; Noy A
J Clin Oncol; 2014 Feb; 32(5):402-8. PubMed ID: 24378417
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
25. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
26. The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center.
Yang L; Wang Q; Hou Y; Zhao J; Li M; Xu D; Zeng X
Clin Rheumatol; 2020 Mar; 39(3):813-821. PubMed ID: 31713733
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
[TBL] [Abstract][Full Text] [Related]
28. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
[TBL] [Abstract][Full Text] [Related]
29. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease.
Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S
Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409
[TBL] [Abstract][Full Text] [Related]
30. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
[TBL] [Abstract][Full Text] [Related]
31. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.
Martyanov V; Kim GJ; Hayes W; Du S; Ganguly BJ; Sy O; Lee SK; Bogatkevich GS; Schieven GL; Schiopu E; Marangoni RG; Goldin J; Whitfield ML; Varga J
PLoS One; 2017; 12(11):e0187580. PubMed ID: 29121645
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Bournia VK; Evangelou K; Sfikakis PP
Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
[TBL] [Abstract][Full Text] [Related]
33. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
34. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
36. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma.
Domiciano DS; Bonfá E; Borges CT; Kairalla RA; Capelozzi VL; Parra E; Christmann RB
Clin Rheumatol; 2011 Feb; 30(2):223-9. PubMed ID: 20544245
[TBL] [Abstract][Full Text] [Related]
37. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
[TBL] [Abstract][Full Text] [Related]
38. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
Furuya Y; Kuwana M
J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
[TBL] [Abstract][Full Text] [Related]
39. Molecular framework for response to imatinib mesylate in systemic sclerosis.
Chung L; Fiorentino DF; Benbarak MJ; Adler AS; Mariano MM; Paniagua RT; Milano A; Connolly MK; Ratiner BD; Wiskocil RL; Whitfield ML; Chang HY; Robinson WH
Arthritis Rheum; 2009 Feb; 60(2):584-91. PubMed ID: 19180499
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
